EWING, N.J.--(BUSINESS WIRE)--BioLeap, Inc. today announced the appointment of Keith Mackay as Vice President, Sales, in a further step toward the successful commercialization of the company’s novel molecular-design technology.
Mr. Mackay brings to BioLeap broad experience in marketing innovative technologies in the life-sciences industry. Over the course of his career, he has managed technology-licensing and service-provision activities for companies including Merck & Co., Inc., DSM, MerckSerono, Codexis, Inc., and GVK Biosciences, Inc. He holds a Bachelor’s degree in Chemistry and an MBA in Finance.
“Keith has demonstrated both the technical expertise required to introduce our proprietary technology to potential partners and the customer focus to make that technology fit well with each partner’s specific needs,” said David Pompliano, Ph.D., Chief Executive Officer of BioLeap.
“We will continue to focus on making our computational fragment-based drug design available to the pharmaceutical and biotechnology industries, both on a project basis and in collaboration. We will be looking to collaborate on our own developing pipeline as well as to help our partners progress their pipelines.
“At the same time, we will also expand our alliances with other industries that rely upon novel molecular design to keep their competitive edge. Our recent agreements with companies in agrochemicals and health-related consumer products as well as pharmaceuticals make clear that our technology platform has wide-ranging applications.”
BioLeap chemists have made proprietary advances in creating and using computer simulations both to design compounds de novo, chemical fragment by chemical fragment, and to tailor existing compound designs. Every BioLeap design builds on calculations of the binding energies between the compound being fashioned in silico and its biological target.
The exactitude of this method seeks to ensure greater affinity for the target than is available through conventional compound screening and to achieve other optimal chemical properties. The method thus promises to reduce costly and time-consuming trial and error, minimizing the number of compounds that actually need to be synthesized and then tested, improving the odds of success in early research, and accelerating overall product development.
BioLeap is a pioneer in computational fragment-based molecular design. In pharmaceutical applications, the company uses its proprietary software to design drug candidates both through its internal programs and in collaboration with partners. BioLeap thus addresses one of the biggest problems in drug discovery: the limitation of drug-like and patentable leads for important but often difficult biological targets. This in silico design capability also finds application in product development for the consumer-product and agriculture industries, promising to achieve greater speed, economy, and odds of success than traditional compound screening. More information is available at www.bioleap.com.